Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference
Synaptogenix, Inc. (OTC: SNPX) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled virtually for March 9-10, 2021. The presentation will feature CEO Alan Tuchman M.D. and President Daniel Alkon M.D., available on-demand starting at 7 a.m. EST on March 9. Synaptogenix focuses on developing therapies for neurodegenerative diseases, with its lead candidate, Bryostatin-1, showing promise in treating Alzheimer's and other conditions. The company has received Orphan Drug Designation from the FDA for Bryostatin-1 for Fragile X syndrome.
- None.
- None.
NEW YORK, March 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 2021.
The presentation will feature the company's CEO, Alan Tuchman M.D., as well as its President and Chief Scientific Officer, Daniel Alkon, M.D. It will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021. For those interested in attending, visit the H.C. Wainwright Conference site to register. Alternatively, the webcast can be accessed directly via the following link: Synaptogenix Presentation @ H.C. Wainwright. If you would like to schedule a meeting with Synaptogenix at the H.C. Wainwright Conference, you can do so through the "meeting management" section of the conference portal.
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel neuro-regenerative drug therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease ("AD"), and preclinical studies for rare diseases such as Fragile X syndrome, Niemann-Pick Type C disease, and Rett syndrome, as well as multiple sclerosis, autistic spectrum disorder, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,600 people in cancer and AD studies, thus creating a large safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Investor Relations
Brett Maas
Hayden IR
brett@haydenir.com
(646)536-7331
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@neurotrope.com
View original content:http://www.prnewswire.com/news-releases/synaptogenix-to-present-at-the-hc-wainwright-global-life-sciences-conference-301241390.html
SOURCE Synaptogenix, Inc.
FAQ
When is Synaptogenix presenting at the H.C. Wainwright Conference?
Who will present at the Synaptogenix conference?
What is the focus of Synaptogenix?
What is Bryostatin-1?
Has Bryostatin-1 received any regulatory designations?
